|
1
|
Parrella P: Epigenetic signatures in
breast cancer: clinical perspective. Breast Care. 5:66–73. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rouault JP, Rimokh R, Tessa C, Paranhos G,
Ffrench M, Duret L, Garoccio M, Germain D, Samarut J and Magaud JP:
BTG1, a member of a new family of antiproliferative genes. EMBO J.
11:1663–1670. 1992.PubMed/NCBI
|
|
3
|
Berthet C, Guehenneux F, Revol V, Samarut
C, Lukaszewicz A, Dehay C, Dumontet C, Magaud JP and Rouault JP:
Interaction of PRMT1 with BTG/TOB proteins in cell signalling:
molecular analysis and functional aspects. Genes Cells. 7:29–39.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Matsuda S, Rouault J, Magaud J and Berthet
C: In search of a function for the TIS21/PC3/BTG1/TOB family. FEBS
Lett. 497:67–72. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bakker WJ, Blazquez-Domingo M, Kolbus A,
Besooyen J, Steinlein P, Beug H, Coffer PJ, Lowenberg B, von
Lindern M and van Dijk TB: FoxO3a regulates erythroid
differentiation and induces BTG1, an activator of protein arginine
methyl transferase 1. J Cell Biol. 164:175–184. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hata K, Nishijima K and Mizuguchi J: Role
for Btg1 and Btg2 in growth arrest of WEHI-231 cells through
arginine methylation following membrane immunoglobulin engagement.
Exp Cell Res. 313:2356–2366. 2007. View Article : Google Scholar
|
|
7
|
van Galen JC, Kuiper RP, van Emst L,
Levers M, Tijchon E, Scheijen B, Waanders E, van Reijmersdal SV,
Gilissen C, van Kessel AG, et al: BTG1 regulates glucocorticoid
receptor autoinduction in acute lymphoblastic leukemia. Blood.
115:4810–4819. 2010.PubMed/NCBI
|
|
8
|
Prevot D, Voeltzel T, Birot AM, Morel AP,
Rostan MC, Magaud JP and Corbo L: The leukemia-associated protein
Btg1 and the p53-regulated protein Btg2 interact with the
homeoprotein Hoxb9 and enhance its transcriptional activation. J
Biol Chem. 275:147–153. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Prevot D, Morel AP, Voeltzel T, Rostan MC,
Rimokh R, Magaud JP and Corbo L: Relationships of the
antiproliferative proteins BTG1 and BTG2 with CAF1, the human
homolog of a component of the yeast CCR4 transcriptional complex:
involvement in estrogen receptor alpha signaling pathway. J Biol
Chem. 276:9640–9648. 2001. View Article : Google Scholar
|
|
10
|
Busson M, Carazo A, Seyer P, Grandemange
S, Casas F, Pessemesse L, Rouault JP, Wrutniak-Cabello C and
Cabello G: Coactivation of nuclear receptors and myogenic factors
induces the major BTG1 influence on muscle differentiation.
Oncogene. 24:1698–1710. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Corjay MH, Kearney MA, Munzer DA, Diamond
SM and Stoltenborg JK: Antiproliferative gene BTG1 is highly
expressed in apoptotic cells in macrophage-rich areas of advanced
lesions in Watanabe heritable hyperlipidemic rabbit and human. Lab
Invest. 78:847–858. 1998.PubMed/NCBI
|
|
12
|
Lee H, Cha S, Lee MS, Cho GJ, Choi WS and
Suk K: Role of antiproliferative B cell translocation gene-1 as an
apoptotic sensitizer in activation-induced cell death of brain
microglia. J Immunol. 171:5802–5811. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rodier A, Marchal-Victorion S, Rochard P,
Casas F, Cassar-Malek I, Rouault JP, Magaud JP, Mason DY, Wrutniak
C and Cabello G: BTG1: a triiodothyronine target involved in the
myogenic influence of the hormone. Exp Cell Res. 249:337–348. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cho JW, Kim JJ, Park SG, Lee DH, Lee SC,
Kim HJ, Park BC and Cho S: Identification of B-cell translocation
gene 1 as a biomarker for monitoring the remission of acute myeloid
leukemia. Proteomics. 4:3456–3463. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Farhana L, Dawson M, Rishi AK, Zhang Y,
Van Buren E, Trivedi C, Reichert U, Fang G, Kirschner MW and
Fontana JA: Cyclin B and E2F-1 expression in prostate carcinoma
cells treated with the novel retinoid CD437 are regulated by the
ubiquitin-mediated pathway. Cancer Res. 62:3842–3849.
2002.PubMed/NCBI
|
|
16
|
Musgrove EA, Hamilton JA, Lee CS, Sweeney
KJ, Watts CK and Sutherland RL: Growth factor, steroid, and steroid
antagonist regulation of cyclin gene expression associated with
changes in T-47D human breast cancer cell cycle progression. Mol
Cell Biol. 13:3577–3587. 1993.PubMed/NCBI
|
|
17
|
Hwang A, McKenna WG and Muschel RJ: Cell
cycle-dependent usage of transcriptional start sites. A novel
mechanism for regulation of cyclin B1. J Biol Chem.
273:31505–31509. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hershko A: Mechanisms and regulation of
the degradation of cyclin B. Philos Trans R Soc Lond B Biol Sci.
354:1571–1576. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vorlaufer E and Peters JM: Regulation of
the cyclin B degradation system by an inhibitor of mitotic
proteolysis. Mol Biol Cell. 9:1817–1831. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Quelle DE, Ashmun RA, Shurtleff SA, Kato
JY, Bar-Sagi D, Roussel MF and Sherr CJ: Overexpression of mouse
D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes
Dev. 7:1559–1571. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ewen ME and Lamb J: The activities of
cyclin D1 that drive tumorigenesis. Trends Mol Med. 10:158–162.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Arnold A and Papanikolaou A: Cyclin D1 in
breast cancer pathogenesis. J Clin Oncol. 23:4215–4224. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nahta R and Esteva FJ: Bcl-2 antisense
oligonucleotides: a potential novel strategy for the treatment of
breast cancer. Semin Oncol. 30:143–149. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ghobrial IM, Witzig TE and Adjei AA:
Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin.
55:178–194. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kymionis GD, Dimitrakakis CE,
Konstadoulakis MM, Arzimanoglou I, Leandros E, Chalkiadakis G,
Keramopoulos A and Michalas S: Can expression of apoptosis genes,
bcl-2 and bax, predict survival and responsiveness to chemotherapy
in node-negative breast cancer patients? J Surg Res. 99:161–168.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cohen GM: Caspases: the executioners of
apoptosis. Biochem J. 326:1–16. 1997.
|
|
27
|
Thornberry NA and Lazebnik Y: Caspases:
enemies within. Science. 281:1312–1316. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kuida K, Zheng TS, Na S, Kuan C, Yang D,
Karasuyama H, Rakic P and Flavell RA: Decreased apoptosis in the
brain and premature lethality in CPP32-deficient mice. Nature.
384:368–372. 1996. View
Article : Google Scholar : PubMed/NCBI
|
